Abstract
Alzheimers disease is an age-related neurodegenerative disease which causes global loss of cognitive function. Drug treatment for Alzheimers disease has been limited to agents that ameliorate behavioral symptoms but these agents are without effect on disease progression. Rational drug design for the treatment of Alzheimers disease now seems possible. As a result of major advances in medical research in this area, knowledge of the etiology of Alzheimers disease is rapidly being understood. This information has uncovered relevant and novel targets for treatment. At the center of the etiological progression of this disease is β-amyloid. A substantial body of evidence strongly suggests that this small protein is critical to the development of Alzheimers disease. The β-amyloid protein is generated by two different proteolytic cleavages. Recently, the proteases responsible for producing the β-amyloid protein have been identified. The proteases represent viable targets for therapeutic intervention against Alzheimers disease. In this review, we describe the biological characteristics of the β-amyloid-forming proteases in the context of pharmaceutical development.
Keywords: Amyloid, Proteases, Alzheimers Disease
Current Pharmaceutical Design
Title: Amyloid Forming Proteases: Therapeutic Targets for Alzheimers Disease
Volume: 8 Issue: 28
Author(s): Frauke Schimmoller, Jeffrey N. Higaki and Barbara Cordell
Affiliation:
Keywords: Amyloid, Proteases, Alzheimers Disease
Abstract: Alzheimers disease is an age-related neurodegenerative disease which causes global loss of cognitive function. Drug treatment for Alzheimers disease has been limited to agents that ameliorate behavioral symptoms but these agents are without effect on disease progression. Rational drug design for the treatment of Alzheimers disease now seems possible. As a result of major advances in medical research in this area, knowledge of the etiology of Alzheimers disease is rapidly being understood. This information has uncovered relevant and novel targets for treatment. At the center of the etiological progression of this disease is β-amyloid. A substantial body of evidence strongly suggests that this small protein is critical to the development of Alzheimers disease. The β-amyloid protein is generated by two different proteolytic cleavages. Recently, the proteases responsible for producing the β-amyloid protein have been identified. The proteases represent viable targets for therapeutic intervention against Alzheimers disease. In this review, we describe the biological characteristics of the β-amyloid-forming proteases in the context of pharmaceutical development.
Export Options
About this article
Cite this article as:
Schimmoller Frauke, Higaki N. Jeffrey and Cordell Barbara, Amyloid Forming Proteases: Therapeutic Targets for Alzheimers Disease, Current Pharmaceutical Design 2002; 8 (28) . https://dx.doi.org/10.2174/1381612023392658
DOI https://dx.doi.org/10.2174/1381612023392658 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diet, Cardiometabolic Factors and Type-2 Diabetes Mellitus: The Role of Genetics
Current Diabetes Reviews Synthesis and Enzymological Characterization of Some 2-(Substitutedphenylamino) quinazolin-4(3H)-one Derivatives as Potent α-Glucosidase Inhibitors In Vitro
Letters in Drug Design & Discovery Upregulated Retinol Binding Protein and Transthyretin as Predictive Biomarkers of Gestational Diabetes Mellitus
Current Proteomics Endoplasmic Reticulum Stress and Bipolar Disorder - Almost Forgotten Therapeutic Drug Targets in the Unfolded Protein Response Pathway Revisited
CNS & Neurological Disorders - Drug Targets Subject Index To Volume 12
Current Pharmaceutical Design The Growth Hormone Secretagogue Receptor (Ghs-R)
Current Pharmaceutical Design Nutrigenomic Analysis of Diet-Gene Interactions on Functional Supplements for Weight Management
Current Genomics Type 1 Diabetes Treatments Based on Stem Cells
Current Diabetes Reviews Statins: Are They All the Same?
Current Drug Therapy Molecular Imaging of Vascular Inflammation
Current Pharmaceutical Design The Role of Renal Nerve Ablation for the Management of Resistant Hypertension and other Disease Conditions: Benefits and Concerns
Current Vascular Pharmacology Editorial (Thematic Issue: Linkage of Neurodegenerative Disorders with Other Health Issues – Volume II)
CNS & Neurological Disorders - Drug Targets Effect on Serum Uric Acid Levels of Drugs Prescribed for Indications other than Treating Hyperuricaemia
Current Pharmaceutical Design Antimicrobial peptides for the treatment of pulmonary tuberculosis, allies or foes?
Current Pharmaceutical Design Molecular Docking Studies of Novel Arylidene-2, 4-Thiazolidinediones as Potential Aldose Reductase Inhibitors
Letters in Drug Design & Discovery p66 Shc as the Engine of Vascular Aging
Current Vascular Pharmacology The Valsalva Maneuver and Alzheimers Disease: Is there a link?
Current Alzheimer Research GIP-Based Therapeutics for Diabetes and Obesity
Current Chemical Biology MR Imaging of Pancreatic Islets: Tracking Isolation, Transplantation and Function
Current Pharmaceutical Design Lipid-Lowering Drugs Acting at the Level of the Gastrointestinal Tract
Current Pharmaceutical Design